Status:
UNKNOWN
Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan
Lead Sponsor:
Far Eastern Memorial Hospital
Conditions:
Thoracic Neoplasms
Late Effect of Radiation
Eligibility:
All Genders
20-80 years
Brief Summary
Background: Chemoradiation is an important treatment strategy of locally advanced inoperable or unresectable disease. Radiation dose is an independent predictor of a pathological response. In additio...
Detailed Description
The risk of RT-related heart disease is now well recognized but the underlying mechanisms of its initiation and progression, and the roles played by microvascular damage, fibrosis and atherosclerosis ...
Eligibility Criteria
Inclusion
- Patients with thoracic malignancy who scheduled further locoregional RT.
- Aged 20-80 years old.
- Classified as intermediate to high future CV risk clinically.
Exclusion
- Pre-existing cardiac disease, such as prior myocardial infarction, documented CAD, congestive heart failure.
- Pregnancy.
- Any medical contraindication of stress cardiac SPECT.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01913769
Start Date
July 1 2013
End Date
July 1 2016
Last Update
August 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Far Eastern Memorial Hospital
New Taipei City, Taiwan, 220